{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:06:22Z","timestamp":1789085182133,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Enzalutamide (ENZA) is a second-generation antiandrogen therapy that provides overall survival (OS) benefit for prostate cancer (PC) patients. However, many patients have baseline or develop resistance to ENZA. Currently, no biomarkers are used in clinical decision making to predict the efficacy of ENZA therapy. We aimed to identify cell-free DNA (cfDNA) biomarkers for metastatic castration-resistant prostate cancer (mCRPC) predictive to ENZA response. Comparative whole-exome and transcriptome sequencing was performed on three ENZA-resistant and parental ENZA-sensitive PC cell line pairs. Bioinformatic analysis identified\n                    <jats:italic>UCA1<\/jats:italic>\n                    ,\n                    <jats:italic>ORM1<\/jats:italic>\n                    , and androgen receptor (AR) as candidate markers for serum cfDNA testing. Digital droplet PCR was used to analyze\n                    <jats:italic>UCA1<\/jats:italic>\n                    ,\n                    <jats:italic>ORM1<\/jats:italic>\n                    and\n                    <jats:italic>AR<\/jats:italic>\n                    in cfDNA from serum samples of mCRPC patients who underwent ENZA (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920), abiraterone (ABI;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920) and 40 docetaxel (DOC;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200940) treatment.\n                    <jats:italic>UCA1<\/jats:italic>\n                    copy number gain was significantly associated with reduced OS in ENZA-treated patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.030).\n                    <jats:italic>AR<\/jats:italic>\n                    gain correlated with poorer OS in ABI-treated patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.039), whereas no association was observed in DOC-treated patients. Normal\n                    <jats:italic>AR<\/jats:italic>\n                    and\n                    <jats:italic>UCA1<\/jats:italic>\n                    levels were associated with significantly better OS in ENZA and ABI-treated patients. These findings suggest that\n                    <jats:italic>UCA1<\/jats:italic>\n                    gain may predict reduced efficacy of ENZA treatment, while\n                    <jats:italic>AR<\/jats:italic>\n                    gain indicates decreased effectiveness of ABI but not ENZA and DOC therapies. These results may help support therapeutic decisions in the clinical settings.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-56189-y","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T21:06:53Z","timestamp":1782076013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["UCA1 copy number gain in serum cfDNA predicts next-generation antiandrogen resistance in metastatic castration-resistant prostate cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Anita","family":"Csizmarik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ron","family":"So\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"V\u00e1radi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Magyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Puhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1kos","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Gy\u0151rffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerg\u0151","family":"Holl\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulham","family":"Al-Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Nyir\u00e1dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Szarvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"issue":"5","key":"56189_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371(5), 424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1405095 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"56189_CR2","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain, M. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 378(26), 2465\u20132474. https:\/\/doi.org\/10.1056\/NEJMoa1800536 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"56189_CR3","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher, H. I. et al. Increased survival with Enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1207506 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"32","key":"56189_CR4","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with Enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37(32), 2974\u20132986. https:\/\/doi.org\/10.1200\/JCO.19.00799 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"56189_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland, S. J. et al. Improved outcomes with Enzalutamide in biochemically recurrent prostate cancer. N. Engl. J. Med. 389(16), 1453\u20131465. https:\/\/doi.org\/10.1056\/NEJMoa2303974 (2023).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"56189_CR6","doi-asserted-by":"publisher","first-page":"728 e13","DOI":"10.1016\/j.urolonc.2021.01.030","volume":"39","author":"A Csizmarik","year":"2021","unstructured":"Csizmarik, A., Hadaschik, B., Kramer, G., Nyirady, P. & Szarvas, T. Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer. Urol. Oncol. 39(10), 728 e13-728 e24. https:\/\/doi.org\/10.1016\/j.urolonc.2021.01.030 (2021).","journal-title":"Urol. Oncol."},{"issue":"8","key":"56189_CR7","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/ijc.34159","volume":"151","author":"A Csizmarik","year":"2022","unstructured":"Csizmarik, A. et al. Proteome profiling of Enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer. Int. J. Cancer 151(8), 1405\u20131419. https:\/\/doi.org\/10.1002\/ijc.34159 (2022).","journal-title":"Int. J. Cancer"},{"issue":"3","key":"56189_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41391-023-00713-y","volume":"27","author":"A Csizmarik","year":"2024","unstructured":"Csizmarik, A. et al. Comparative proteome and serum analysis identified FSCN1 as a marker of Abiraterone resistance in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 27(3), 451\u2013456. https:\/\/doi.org\/10.1038\/s41391-023-00713-y (2024).","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"56189_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20(2), 71\u201388. https:\/\/doi.org\/10.1038\/s41576-018-0071-5 (2019).","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"56189_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ajur.2022.11.002","volume":"10","author":"W He","year":"2023","unstructured":"He, W., Xiao, Y., Yan, S., Zhu, Y. & Ren, S. Cell-free DNA in the management of prostate cancer: Current status and future prospective. Asian J. Urol. 10(3), 298\u2013316. https:\/\/doi.org\/10.1016\/j.ajur.2022.11.002 (2023).","journal-title":"Asian J. Urol."},{"issue":"8","key":"56189_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.tig.2021.04.005","volume":"37","author":"DSC Han","year":"2021","unstructured":"Han, D. S. C. & Lo, Y. M. D. The nexus of cfDNA and nuclease biology. Trends Genet. 37(8), 758\u2013770. https:\/\/doi.org\/10.1016\/j.tig.2021.04.005 (2021).","journal-title":"Trends Genet."},{"issue":"11","key":"56189_CR12","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","volume":"27","author":"H Tukachinsky","year":"2021","unstructured":"Tukachinsky, H. et al. Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms. Clin. Cancer Res. 27(11), 3094\u20133105. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4805 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"56189_CR13","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","volume":"28","author":"V Conteduca","year":"2017","unstructured":"Conteduca, V. et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study. Ann. Oncol. 28(7), 1508\u20131516. https:\/\/doi.org\/10.1093\/annonc\/mdx155 (2017).","journal-title":"Ann. Oncol."},{"issue":"2","key":"56189_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41391-020-00309-w","volume":"24","author":"M Del Re","year":"2021","unstructured":"Del Re, M. et al. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. Prostate Cancer Prostatic Dis. 24(2), 524\u2013531. https:\/\/doi.org\/10.1038\/s41391-020-00309-w (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"4","key":"56189_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","volume":"8","author":"M Annala","year":"2018","unstructured":"Annala, M. et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 8(4), 444\u2013457. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0937 (2018).","journal-title":"Cancer Discov."},{"key":"56189_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00424","author":"EM Kwan","year":"2021","unstructured":"Kwan, E. M. et al. Plasma cell-free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.20.00424 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"56189_CR17","doi-asserted-by":"publisher","first-page":"7685","DOI":"10.2147\/CMAR.S200436","volume":"11","author":"F Yao","year":"2019","unstructured":"Yao, F., Wang, Q. & Wu, Q. The prognostic value and mechanisms of lncRNA UCA1 in human cancer. Cancer Manag. Res. 11, 7685\u20137696. https:\/\/doi.org\/10.2147\/CMAR.S200436 (2019).","journal-title":"Cancer Manag. Res."},{"issue":"16","key":"56189_CR18","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1158\/1078-0432.CCR-06-0134","volume":"12","author":"XS Wang","year":"2006","unstructured":"Wang, X. S. et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin. Cancer Res. 12(16), 4851\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0134 (2006).","journal-title":"Clin. Cancer Res."},{"key":"56189_CR19","doi-asserted-by":"publisher","first-page":"6357","DOI":"10.2147\/CMAR.S186108","volume":"10","author":"F Yazarlou","year":"2018","unstructured":"Yazarlou, F. et al. Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer. Cancer Manag. Res. 10, 6357\u20136365. https:\/\/doi.org\/10.2147\/CMAR.S186108 (2018).","journal-title":"Cancer Manag. Res."},{"key":"56189_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3729830","volume":"2016","author":"XD Sun","year":"2016","unstructured":"Sun, X. D. et al. Clinical significance of UCA1 to predict metastasis and poor prognosis of digestive system malignancies: A meta-analysis. Gastroenterol. Res. Pract. 2016, 3729830. https:\/\/doi.org\/10.1155\/2016\/3729830 (2016).","journal-title":"Gastroenterol. Res. Pract."},{"issue":"2","key":"56189_CR21","first-page":"366","volume":"9","author":"S Zhang","year":"2017","unstructured":"Zhang, S., Dong, X., Ji, T., Chen, G. & Shan, L. Long non-coding RNA UCA1 promotes cell progression by acting as a competing endogenous RNA of ATF2 in prostate cancer. Am. J. Transl. Res. 9(2), 366\u2013375 (2017).","journal-title":"Am. J. Transl. Res."},{"key":"56189_CR22","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181465","author":"C He","year":"2019","unstructured":"He, C. et al. LncRNA UCA1 acts as a sponge of miR-204 to up-regulate CXCR4 expression and promote prostate cancer progression. Biosci. Rep. https:\/\/doi.org\/10.1042\/BSR20181465 (2019).","journal-title":"Biosci. Rep."},{"key":"56189_CR23","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5611","author":"Z Li","year":"2024","unstructured":"Li, Z., Yu, D., Li, H., Lv, Y. & Li, S. [Corrigendum] Long non\u2011coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2\/p21 axis and the PI3K\/AKT signaling pathway. Int. J. Oncol. https:\/\/doi.org\/10.3892\/ijo.2024.5611 (2024).","journal-title":"Int. J. Oncol."},{"issue":"7","key":"56189_CR24","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/febs.12737","volume":"281","author":"Y Fan","year":"2014","unstructured":"Fan, Y. et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 281(7), 1750\u20138. https:\/\/doi.org\/10.1111\/febs.12737 (2014).","journal-title":"FEBS J."},{"issue":"6","key":"56189_CR25","doi-asserted-by":"publisher","first-page":"949","DOI":"10.17305\/bjbms.2022.7268","volume":"22","author":"J Gu","year":"2022","unstructured":"Gu, J. et al. ORM 1 as a biomarker of increased vascular invasion and decreased sorafenib sensitivity in hepatocellular carcinoma. Bosn. J. Basic Med. Sci. 22(6), 949\u2013958. https:\/\/doi.org\/10.17305\/bjbms.2022.7268 (2022).","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"56189_CR26","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.2147\/IJGM.S355435","volume":"15","author":"J Wei","year":"2022","unstructured":"Wei, J. et al. Identification of potential predictor of biochemical recurrence in prostate cancer. Int. J. Gen. Med. 15, 4897\u20134905. https:\/\/doi.org\/10.2147\/IJGM.S355435 (2022).","journal-title":"Int. J. Gen. Med."},{"key":"56189_CR27","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1200\/PO.20.00084","volume":"4","author":"SH Tolmeijer","year":"2020","unstructured":"Tolmeijer, S. H. et al. A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. JCO Precis Oncol. 4, 714\u2013729 (2020).","journal-title":"JCO Precis Oncol."},{"issue":"7","key":"56189_CR28","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26(7), 1148\u201359. https:\/\/doi.org\/10.1200\/JCO.2007.12.4487 (2008).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56189-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56189-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56189-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:16:24Z","timestamp":1789082184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56189-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56189"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56189-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BH: consulting fees from Janssen, Bayer, ABX, Astellas, Merck, Amgen, MSD\/Pfizer, Novartis, BMS, Monrol, Onkowissen, POINT Biopharma, Ipsen, AstraZeneca, Lightpoint medical, Telix, and Accord Healthcare; travel support from AstraZeneca, BMS, Janssen, Bayer, and Ipsen; grants or contracts from Janssen, Deutsche Forschungsgesellschaft, Novartis, and BMS; participation on data safety monitoring boards for Janssen and ABX. Further authors declare that they have no financial interest in the subject matter or materials discussed in this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided written consent, and the study was performed in accordance with ethical standards of the Helsinki Declaration and approved by the ethical boards of the hospitals (TUKEB 55\/2014, ECS 1986\/2017).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28420"}}